Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
NurExone Biologic Inc.
NRXBF
Primary Symbol:
V.NRX
Healthcare
Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following...
spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (TSXV:NRX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Comment by
RealREIT$
on Nov 30, 2023 3:20pm
RE:Undervalued Israeli Biotech : NurExone Biologic Inc
This should see a lot more attention with their developments. Orphan Drug Designation should have boosted this to $0.50 easily.
(8)
•••
Brice978
X
View Profile
View Bullboard History
Post by
Brice978
on Nov 28, 2023 3:00pm
Undervalued Israeli Biotech : NurExone Biologic Inc
Undervalued Israeli Biotech : NurExone Biologic Inc (TSXV: NRX) https://10xalerts.com/undervalued-israeli-biotech-nurexone-biologic-inc-tsxv-nrx/
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Oct 30, 2023 4:50pm
Potential market disrupter
Even for alzeimer and dementia i suppose
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Comment by
RealREIT$
on Oct 30, 2023 1:15pm
RE:NurExone Biologic Receives FDA Orphan-Drug Designation
https://www.americangene.com/blog/benefits-of-fda-orphan-drug-designation-what-you-need-to-know/
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Post by
RealREIT$
on Oct 30, 2023 1:11pm
NurExone Biologic Receives FDA Orphan-Drug Designation
https://www.globenewswire.com/news-release/2023/10/30/2769335/0/en/NurExone-Biologic-Receives-FDA-Orphan-Drug-Designation-Accelerating-Development-of-ExoPTEN-therapy-for-Acute-Spinal-Cord-Injury
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 11, 2023 8:30am
New Press Release - NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy
TORONTO and HAIFA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with acute spinal cord injuries (“SCI”), is...
read article.
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Post by
RealREIT$
on Oct 05, 2023 11:09am
NurExone May Hold The Key To Potential Breakthrough In Acute
An estimated 250,000-500,000 people experience a Spinal Cord Injury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently
...more
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Post by
RealREIT$
on Oct 05, 2023 11:07am
NurExone May Hold The Key To Potential Breakthrough In Acute
Get to Know ExoTherapy and ExoPTEN One of the key assets of NurExone's technology is its drug delivery system, branded ExoTherapy. ExoTherapy is a play on the combination of exosomes with
...more
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Post by
RealREIT$
on Oct 05, 2023 11:06am
NurExone May Hold The Key To Potential Breakthrough In Acute
https://us11.campaign-archive.com/?u=3204f2d2592a7d2ac80467b2f&id=39bb6d2c60
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Post by
RealREIT$
on Sep 13, 2023 12:45pm
NurExone Moves Forward Towards Human Clinical Trials, Comple
Taking a starter psotion here.
(2)
•••
RealREIT$
X
View Profile
View Bullboard History
Post by
RealREIT$
on Sep 13, 2023 12:44pm
NurExone Moves Forward Towards Human Clinical Trials
https://www.globenewswire.com/news-release/2023/09/13/2742459/0/en/NurExone-Moves-Forward-Towards-Human-Clinical-Trials-Completes-Pre-IND-Meeting-with-the-FDA-for-Proprietary-ExoPTEN-Drug.html
(3214)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Jun 22, 2023 3:19pm
Regeneration & Reinnervation of Spinal Cord in Rats Treated
TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive
...more
(4)
•••
ThesisCapital
X
View Profile
View Bullboard History
Post by
ThesisCapital
on Nov 30, 2022 10:28pm
NurExone: Loading Exosomes with Therapeutic Molecules
NurExone reported today results of a pre-clinical loading efficiency study that was completed by the Company showing that its innovative and proprietary loading technology has the potential to serve
...more
(1)
•••
dkeller85
X
View Profile
View Bullboard History
Post by
dkeller85
on Mar 20, 2022 6:49am
Progress Update on RTO with Nurexone Biologic
Hot off the press: Calgary, Alberta--(Newsfile Corp. - March 15, 2022) - EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) ("EnerSpar" or the "Company") is pleased to announce it
...more
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden